Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease

Brad P. Dieter, Sterling M. McPherson, Maryam Afkarian, Ian H. de Boer, Rajnish Mehrotra, Robert Short, Celestina Barbosa-Leiker, Radica Z. Alicic, Rick L. Meek, Katherine R. Tuttle

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Aims To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. Methods In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. Results Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean ± SD age of 57 ± 7.5 years. At baseline, participants had hemoglobin A1c of 8.6 ± 2.3%, systolic blood pressure of 153 ± 27 mm Hg, body mass index of 31 ± 9 kg/m2, median urine-albumin-to-creatinine ratio of 1861 mg/g (interquartile range 720–3912 mg/g), and estimated glomerular filtration rate of 55.7 ± 22.3 ml/min/1.73 m2. Over a median duration of follow-up of 3.5 years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43–6.40, p = 0.003) in the highest (> 1.0 μg/ml) compared to the lowest (< 0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c = 0.017). Conclusions In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.

Original languageEnglish (US)
Pages (from-to)1467-1472
Number of pages6
JournalJournal of Diabetes and its Complications
Volume30
Issue number8
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Keywords

  • Biomarkers
  • Chronic kidney disease
  • Diabetes
  • Inflammation
  • Risk-stratification

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease'. Together they form a unique fingerprint.

  • Cite this

    Dieter, B. P., McPherson, S. M., Afkarian, M., de Boer, I. H., Mehrotra, R., Short, R., Barbosa-Leiker, C., Alicic, R. Z., Meek, R. L., & Tuttle, K. R. (2016). Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. Journal of Diabetes and its Complications, 30(8), 1467-1472. https://doi.org/10.1016/j.jdiacomp.2016.07.018